Clinical trials: Multiple Sclerosis (MS)
Multiple Sclerosis
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial
The purpose of this study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months, or until it becomes commercially available whichever comes first, in subjects who…
- Trial name
- NCT00648908
- Testing
- Fampridine-SR
- Where
- 32 sites in United States, Canada
- Volunteers
- 269 people
- Sponsor
- Acorda Therapeutics
Relapsing-remitting Multiple Sclerosis
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with RRMS aged between 10 and < 18 years over a flexible duration.
- Trial name
- Operetta 2 (NCT05123703)
- Testing
- Ocrelizumab, Fingolimod
- Where
- 71 sites in United States, Argentina and 23 more
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche
Relapsing Remitting Multiple Sclerosis
A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2
The objectives of this study are to evaluate the utility of two gastrointestinal (GI) symptom scales (Individual GI Symptom and Impact Scale {IGISIS} and Global GI Symptom and Impact Scale {GGISIS}) in assessing GI tolerability…
- Trial name
- NCT03093324
- Testing
- ALKS 8700, Dimethyl Fumarate
- Where
- 67 sites in United States, Germany and 1 more
- Volunteers
- 506 people
- Sponsor
- Biogen
Multiple Sclerosis
Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks
This study will evaluate if patients who had a serious cardiovascular event upon initiation of fingolimod are at risk to delevop long term other cardiovascular events
- Trial name
- NCT02232061
- Testing
- Fingolimod
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue
The overarching aim is to assess the role of microglial activation and norepinephrine transporter binding in pathogenesis of MS-related fatigue, using novel Positron Emission Tomography (PET) radiotracers, [F-18]PBR06 and…
- Trial name
- NCT04144257
- Testing
- [F-18]PBR06, [C-11]Methylreboxetine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Brigham and Women's Hospital
Progressive Multiple Sclerosis
A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis
This study aims to identify the safety and tolerability of bile acid supplementation in patients with progressive Multiple Sclerosis (MS).
- Trial name
- NCT03423121
- Testing
- Tauroursodeoxycholic Acid
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Johns Hopkins University
Relapsing-Remitting Multiple Sclerosis
High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study
The purpose of this study is to determine the effectiveness of a new treatment for multiple sclerosis (MS), a serious disease in which the immune system attacks the brain and spinal cord.
- Trial name
- NCT00288626
- Testing
- Granulocyte-colony stimulating factor (G-CSF) and prednisone, Carmustine, etoposide, cytarabine, and melphalan (BEAM), Autologous hematopoietic stem cell transplant
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis (MS)
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis
The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with progressive Multiple Sclerosis (PMS).
- Trial name
- NCT03737812
- Testing
- elezanumab
- Where
- 37 sites in United States, Canada
- Volunteers
- 123 people
- Sponsor
- AbbVie
Multiple Sclerosis, Spasticity, Muscle
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
Multiple Sclerosis (MS) is an acquired inflammatory demyelinating disease of the central nervous system (CNS) that is regarded as the foremost cause of non-traumatic neurologic disability in adults in North America.
- Trial name
- OS440-3004 (NCT03290131)
- Testing
- Arbaclofen
- Where
- 30 sites in Belarus, Bosnia and Herzegovina and 5 more
- Volunteers
- 536 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Neuropathic Pain, Chronic Pain
Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis
This study will determine whether treatment with an extended-release opioid or topical lidocaine is effective in relieving distal symmetric lower extremity burning pain associated with multiple sclerosis (MS).
- Conditions
- Neuropathic Pain, Chronic Pain, Multiple Sclerosis
- Trial name
- NCT00414453
- Testing
- Lidocaine patch 5%, Extended-release oxycodone
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Rochester
Multiple Sclerosis
Activity and Balanced Eating to Reduce Comorbidities and Symptoms of MS
Multiple sclerosis (MS) is the leading cause of irreversible neurological disability among young women and the second leading cause of disability among young men in the U.S.
- Trial name
- ABC's of MS (NCT03808545)
- Testing
- Behavioral Intervention for Physical Activity in Multiple Sclerosis (BIPAMS), BIPAMS + Diet
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Alabama at Birmingham
Multiple Sclerosis, Relapsing-Remitting
Measurement of Relaxin Peptide in Multiple Sclerosis (MS)
This study will evaluate relaxin (RLX) levels in patients with multiple sclerosis.
- Trial name
- NCT01909492
- Testing
- Blood Draw, Lumbar Puncture
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Providence Health & Services
Multiple Sclerosis
Protective Stepping in People With MS
Falls are common in Veterans with multiple sclerosis (MS), and current rehabilitation approaches to reduce falls are inadequate.
- Trial name
- PRO-STEP (NCT03551665)
- Testing
- Protective step training
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis, Fatigue
Ketamine for Treatment of MS Fatigue
Multiple sclerosis (MS) is an inflammatory, demyelinating and degenerative disease of the central nervous system and, after trauma, is the most common cause of disability in young adults, affecting more than 400,000 individuals…
- Trial name
- NCT03500289
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis
Memantine for Spasticity in MS Patients
Participants (n=20) will be identified at routine care visits performed at the Rochester Multiple Sclerosis Center. Eligible participants will have MS by McDonald Criteria,7 and will have a modified Ashworth spasticity rating8 of…
- Trial name
- NCT00638027
- Testing
- memantine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Rochester
Relapsing Multiple Sclerosis
Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab
This study aimed to understand whether patients with relapsing multiple sclerosis (RMS) can mount an immune response to SARS-CoV-2 mRNA vaccines (initial vaccinations or booster vaccines) when vaccinated either before initiation…
- Trial name
- KYRIOS (NCT04869358)
- Testing
- Ofatumumab
- Where
- 6 sites in Germany
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis
Natalizumab (Tysabri) Re-Initiation of Dosing
The primary objectives for the initial treatment period of this study are to further evaluate the safety of natalizumab monotherapy by evaluating the risk of hypersensitivity reactions and immunogenicity following re-exposure to…
- Trial name
- STRATA (NCT00297232)
- Testing
- Natalizumab
- Where
- 112 sites in Australia, Belgium and 19 more
- Volunteers
- 1,094 people
- Sponsor
- Biogen
Multiple Sclerosis
An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis
This study was an extension study of NCT00537082. This study was designed to evaluate the efficacy and safety of long-term administration of 0.5 mg or 1.25 mg of fingolimod (FTY720) to relapsing multiple sclerosis.
- Trial name
- NCT00670449
- Testing
- Fingolimod
- Where
- 20 sites in Japan
- Volunteers
- 143 people
- Sponsor
- Novartis
Relapsing Multiple Sclerosis
The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial
This study, REbif® vs Glatiramer acetate in relapsing multiple sclerosis (MS) disease - pharmacogenetic(s) (REGARD-PGx) is a single blood sampling exploratory pharmacogenetic study of the REGARD trial.
- Trial name
- REGARD-PGx (NCT01034579)
- Testing
- Blood sampling
- Where
- United States
- Volunteers
- 324 people
- Sponsor
- EMD Serono
Multiple Sclerosis
Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS
The primary objective of this study is to determine if monthly pulse doses of a three-day course ACTH (H.P. Acthar®) is more effective at recovering myelin at 12 months, as measured by myelin water fraction (MWF), in new multiple…
- Trial name
- NCT02446886
- Testing
- Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University